Mounjaro®
Starting from £179.99/mo
Start journey Learn moreLow mood or depression-like feelings reported during Mounjaro treatment can, for many people, ease as the body adjusts — but they don't always resolve on their own, and the picture is more nuanced than a simple yes. Mounjaro (tirzepatide) affects appetite, gut hormones and metabolic signalling, and any of those changes can influence how you feel mentally in the early weeks. Because these are prescription-only medicines, a prescriber needs to know if low mood persists: it changes what happens next. The rest of this page walks through what is actually known, what typically happens across the treatment timeline, and when the right step is to get clinical help rather than wait it out.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first, most practically useful step is to notice exactly when the low mood appeared. Did it begin in the first two weeks after starting or after a dose increase? Or has it been building gradually over months? Timing matters because the likely explanation (and the right response) differs between those two patterns.
Early-onset low mood, arriving in the first week or two of a new dose, is sometimes tied to the GI side-effect cluster: persistent nausea, poor sleep from digestive discomfort and a sharp drop in the pleasure most people unconsciously get from eating. Those are real physiological stressors, and feeling flat or irritable because of them is not the same thing as a depressive episode. Many people find this phase settles as nausea eases, usually within two to four weeks. Our page on whether Mounjaro can cause depression goes deeper into the biological mechanisms behind early mood changes.
Mood that appears later in treatment, or that feels qualitatively different from nausea-related flatness, needs closer attention. It may still resolve; it may need to be actively managed. Keeping a brief daily note (mood, sleep, appetite, energy) for two weeks gives a prescriber something concrete to work with rather than a general impression.
One pattern our clinical team hear described regularly is a feeling of emotional blunting that mirrors the appetite suppression itself. When Mounjaro reduces food cravings and the reward response to eating, some people notice that other sources of pleasure feel muted at the same time. This is not the same as clinical depression, but it can feel alarming, particularly if you weren't expecting it.
This effect (sometimes called food-noise suppression or, in broader terms, what suppression means on Mounjaro) does appear to ease for many people once the body adjusts to the new hormone signalling, and our dedicated page on Mounjaro suppression explains in more detail how that adjustment process tends to unfold. The adjustment period is harder to predict at higher doses. At 10mg or 12.5mg, which carry stronger appetite and reward effects than the 2.5mg starting dose, some people need more time before the emotional tone normalises.
For others, the suppression effect is the first time they have experienced life without constant food preoccupation, and they describe it as relief rather than loss. Individual variation here is wide. There is no single timeline that fits everyone, which is why a prescriber who knows your history is better placed than general guidance to tell you whether waiting is reasonable in your specific case.
Waiting for adjustment is reasonable for mild, clearly nausea-linked flatness in the first fortnight. It is not the right approach if low mood is persistent, worsening, or accompanied by any thoughts of self-harm. The relationship between Mounjaro and depressive symptoms is still being studied, and the MHRA's Yellow Card system exists precisely to capture individual reports that build the evidence base over time. You can report a suspected side effect directly at yellowcard.mhra.gov.uk.
In practice, a prescriber has several options: reviewing whether a dose reduction would help, deciding whether to pause treatment, or considering whether mood support alongside weight management is the better path. None of these decisions should be made by the patient alone by adjusting their own dose. The NHS tirzepatide medicines page lists mood changes and thoughts of self-harm as effects requiring prompt medical attention, not a watch-and-wait approach, and our own tirzepatide information page covers what patients prescribed this medicine in the UK should know about monitoring their symptoms.
If you are managing treatment through nume, the priority aftercare line is available seven days a week, contact the team through the support page rather than waiting for a scheduled review if symptoms are troubling you.
This is worth raising honestly, because the evidence genuinely points in more than one direction. Some people starting GLP-1 treatment report improved mood, reduced anxiety and better energy within the first few months, an effect plausibly connected to early weight loss, improved sleep from reduced joint or reflux symptoms, and the psychological lift of feeling more in control of appetite. Our page on Mounjaro and improved mood covers the emerging evidence on that side of the picture.
The honest answer to whether depression goes away on Mounjaro is therefore: it depends heavily on what's driving it. Nausea-linked flatness in the early weeks often does ease. Persistent or worsening low mood needs clinical review rather than patient-led patience. And for a meaningful number of people, mood actually improves compared with where they started.
Treatment decisions, including whether to continue, adjust or pause, sit with your prescriber. If you haven't started yet and want to understand the full clinical picture before committing, starting a free consultation gives you access to a prescriber who can assess your individual history, including any relevant mental health background, before anything is prescribed.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.